Literature DB >> 26961554

Spontaneous tumour lysis syndrome secondary to the transformation of chronic myelomonocytic leukaemia into acute myeloid leukaemia.

Alexander Langridge1, Kathryn Musgrave2, Yogesh Upadhye3.   

Abstract

A 78-year-old man, with a 6-year history of stable chronic myelomonocytic leukaemia (CMML), presented with general deterioration and worsening pancytopenia. Bone marrow biopsy showed that his disease had transformed into acute myeloid leukaemia (AML). He was started on a supportive transfusion regimen and did not receive any chemotherapy or corticosteroids. Several weeks later, he developed acute renal failure and was admitted to a medical admissions ward. Spontaneous tumour lysis syndrome (sTLS, grade 1) was diagnosed, as per the Cairo and Bishop criteria. He was treated with intravenous fluids, rasburicase and allopurinol. His renal function improved and he recovered from the sTLS. The authors believe that this is the first published case of sTLS occurring as a result of CMML transforming into AML; it highlights the importance of recognising sTLS as a cause of renal failure and electrolyte disturbance before cancer treatment begins. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 26961554      PMCID: PMC4785427          DOI: 10.1136/bcr-2015-213095

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

1.  Renal tubular damage in rasburicase: risks of alkalinisation.

Authors:  H van den Berg; A M Reintsema
Journal:  Ann Oncol       Date:  2004-01       Impact factor: 32.976

2.  Acute tumor lysis syndrome secondary to hydroxycarbamide in chronic myelomonocytic leukemia.

Authors:  Zaher K Otrock; Ali T Taher; Rami A R Mahfouz; Jawad A Makarem; Ali I Shamseddine
Journal:  Am J Hematol       Date:  2006-03       Impact factor: 10.047

3.  Tumor lysis syndrome: current perspective.

Authors:  Jessica Hochberg; Mitchell S Cairo
Journal:  Haematologica       Date:  2008-01       Impact factor: 9.941

4.  Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.

Authors:  C H Pui; H H Mahmoud; J M Wiley; G M Woods; G Leverger; B Camitta; C Hastings; S M Blaney; M V Relling; G H Reaman
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

Review 5.  The management of tumor lysis syndrome.

Authors:  Elvira Rampello; Tiziana Fricia; Mariano Malaguarnera
Journal:  Nat Clin Pract Oncol       Date:  2006-08

6.  Prognostic significance of acute renal injury in acute tumor lysis syndrome.

Authors:  Michael Darmon; Isabelle Guichard; François Vincent; Benoit Schlemmer; Elie Azoulay
Journal:  Leuk Lymphoma       Date:  2010-02

Review 7.  Tumour lysis syndrome: new therapeutic strategies and classification.

Authors:  Mitchell S Cairo; Michael Bishop
Journal:  Br J Haematol       Date:  2004-10       Impact factor: 6.998

8.  A forgotten cause of kidney injury in chronic myelomonocytic leukemia.

Authors:  Tejas V Patel; Helmut G Rennke; J Mark Sloan; Daniel J DeAngelo; David M Charytan
Journal:  Am J Kidney Dis       Date:  2009-01-29       Impact factor: 8.860

9.  Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model.

Authors:  Pau Montesinos; Ignacio Lorenzo; Guillermo Martín; Jaime Sanz; Maria Luz Pérez-Sirvent; David Martínez; Guillermo Ortí; Lorenzo Algarra; Jesus Martínez; Federico Moscardó; Javier de la Rubia; Isidro Jarque; Guillermo Sanz; Miguel A Sanz
Journal:  Haematologica       Date:  2008-01       Impact factor: 9.941

10.  Renal involvement by chronic myelomonocytic leukemia requiring nephroureterectomy.

Authors:  Elias S Hyams; Raavi Gupta; Jonathan Melamed; Samir S Taneja; Ojas Shah
Journal:  Rev Urol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.